tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Perlman RL and Rao PS Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment. 2014 Drugs Aging pmid:24399579
Tanaka K et al. Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases. 2014 J. Hum. Genet. pmid:24352002
Kim EJ et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 2014 Am. J. Transplant. pmid:24354871
Huang K et al. Novel role for NFAT3 in ERK-mediated regulation of CXCR4. 2014 PLoS ONE pmid:25514788
Cho JH et al. Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet. 2014 Eur J Pharm Sci pmid:24388864
Singh K et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 2014 Am. J. Transplant. pmid:25359003
Siebelt M et al. FK506 protects against articular cartilage collagenous extra-cellular matrix degradation. 2014 Osteoarthr. Cartil. pmid:24561282
Tang Q Pharmacokinetics of therapeutic Tregs. 2014 Am. J. Transplant. pmid:25358900
Pereira MJ et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. 2014 J. Clin. Endocrinol. Metab. pmid:25004245
Grillo E et al. Necrobiosis lipoidica. 2014 Aust Fam Physician pmid:24600675
Kimura Y et al. Evaluation of the Multi-ImmunoTox Assay composed of 3 human cytokine reporter cells by examining immunological effects of drugs. 2014 Toxicol In Vitro pmid:24603311
Shilbayeh S The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients. 2014 Saudi J Kidney Dis Transpl pmid:24625991
Sagiroglu T et al. Protective effect of everolimus on renal ischemia reperfusion injury in rats. 2014 Saudi J Kidney Dis Transpl pmid:24625994
Wang XZ et al. Increased intracellular adenosine triphosphate level as an index to predict acute rejection in kidney transplant recipients. 2014 Transpl. Immunol. pmid:24211610
Lapeyraque AL et al. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. 2014 Pediatr. Nephrol. pmid:24435759
Shimizu M et al. Successful multitarget therapy using mizoribine and tacrolimus for refractory Takayasu arteritis. 2014 Rheumatology (Oxford) pmid:24609060
Højfeldt JW et al. Bifunctional ligands allow deliberate extrinsic reprogramming of the glucocorticoid receptor. 2014 Mol. Endocrinol. pmid:24422633
Golubović B et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients--population pharmacokinetic approach. 2014 Eur J Pharm Sci pmid:24184751
Saso S et al. Uterine allotransplantation in a rabbit model using aorto-caval anastomosis: a long-term viability study. 2014 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:25306223
Mekaj AY et al. Application of topical pharmacological agents at the site of peripheral nerve injury and methods used for evaluating the success of the regenerative process. 2014 J Orthop Surg Res pmid:25303779
Satoh S et al. Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation. 2014 Pharmacogenomics pmid:25303300
Meyer KC et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. 2014 Eur. Respir. J. pmid:25359357
Souto-Rodríguez R et al. Differences in the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol. 2014 Transplant. Proc. pmid:25420839
de la Fuente S et al. Long-term survivors after pediatric liver transplatation are at increased risk for development of cardiovascular disease events: analysis of 30 cases. 2014 Transplant. Proc. pmid:25420837
Masson P et al. Belatacept for kidney transplant recipients. 2014 Cochrane Database Syst Rev pmid:25416857
Salehi-Najafabadi Z et al. The gamma-butyrolactone receptors BulR1 and BulR2 of Streptomyces tsukubaensis: tacrolimus (FK506) and butyrolactone synthetases production control. 2014 Appl. Microbiol. Biotechnol. pmid:24562179
Xue W et al. Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. 2014 Chin. Med. J. pmid:24931259
Lalić J et al. Immunosuppressive medication adherence in kidney transplant patients. 2014 Med Princ Pract pmid:24923773
Gijsen VM et al. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study. 2014 Ther Drug Monit pmid:24089076
Demmers MW et al. Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. 2014 Transplantation pmid:24704664
Koren G and Rieder M Measuring oral bioavailability of tacrolimus. 2014 Pediatr Transplant pmid:25250966
Schlegel A et al. Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. 2014 Ann. Surg. pmid:25243553
Størset E et al. Importance of hematocrit for a tacrolimus target concentration strategy. 2014 Eur. J. Clin. Pharmacol. pmid:24071959
Rahman Z et al. Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics. 2014 Int J Pharm pmid:25173870
Jia JJ et al. ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation. 2014 World J. Gastroenterol. pmid:25170223
Hao JC et al. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. 2014 World J. Gastroenterol. pmid:25170222
Peng L et al. The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4. 2014 PLoS ONE pmid:25165975
Elens L et al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. 2014 Ther Drug Monit pmid:24061445
Imataki O et al. Reversible cerebral vasoconstriction syndrome resulted in cerebral infarction after allogeneic stem cell transplantation: a case report. 2014 Ann. Hematol. pmid:24061786
Vattemi G et al. Polymyositis in solid organ transplant recipients receiving tacrolimus. 2014 J. Neurol. Sci. pmid:25130930
Narabayashi K et al. Oral tacrolimus for megacolon in patients with severe ulcerative colitis. 2014 Intern. Med. pmid:25130105
Guy S et al. Successful treatment of acute severe graft-versus-host-disease in a pancreas-after-kidney transplant recipient: case report. 2014 Transplant. Proc. pmid:25179161
Yuan C et al. A simple and robust LC-MS/MS method for measuring sirolimus and everolimus in whole blood. 2014 Bioanalysis pmid:25077621
Kaieda S et al. Successful treatment of rectal ulcers in a patient with systemic lupus erythematosus using corticosteroids and tacrolimus. 2014 Mod Rheumatol pmid:24593214
Aulagnon F et al. Diarrhea after kidney transplantation: a new look at a frequent symptom. 2014 Transplantation pmid:25073040
Bica L et al. Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation. 2014 PLoS ONE pmid:24587210
Han JS et al. Tacrolimus 0.1% ointment in the treatment of allergic contact dermatitis: a new approach. 2014 Int. J. Dermatol. pmid:25070257
Little JA et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. 2014 J. Rheumatol. pmid:24085549
Bergmann TK et al. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. 2014 Ther Drug Monit pmid:24089074
Beermann KJ et al. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. 2014 Clin Transplant pmid:24754564
Denfield SW Oxidative and other stresses following pediatric heart transplantation. 2014 Pediatr Transplant pmid:25250969
Izumi Y et al. Safety of tacrolimus treatment during pregnancy and lactation in systemic lupus erythematosus: a report of two patients. 2014 Tohoku J. Exp. Med. pmid:25175032
Anderson JS et al. Statistical allosteric coupling to the active site indole ring flip equilibria in the FK506-binding domain. 2014 Biophys. Chem. pmid:25016286
van Gelder T et al. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. 2014 Nat Rev Nephrol pmid:25247332
Tapirdamaz Ö et al. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. 2014 Pharmacogenet. Genomics pmid:25014506
Helmschrott M et al. Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen. 2014 Drug Des Devel Ther pmid:25246772
Matta C et al. Ser/Thr-phosphoprotein phosphatases in chondrogenesis: neglected components of a two-player game. 2014 Cell. Signal. pmid:25007994
Matsuda Y et al. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors. 2014 Interact Cardiovasc Thorac Surg pmid:24659549
Hara H et al. Hematopoietic chimerism following allotransplantation of the spleen, splenocytes or kidney in pigs. 2014 Transpl. Immunol. pmid:25245436
Lunde I et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. 2014 Eur. J. Clin. Pharmacol. pmid:24658827
Picchianti-Diamanti A et al. P-glycoprotein and drug resistance in systemic autoimmune diseases. 2014 Int J Mol Sci pmid:24658440
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Sureshkumar KK and Chopra B In search of an optimal induction agent in kidney transplantation. 2014 Transplantation pmid:24978038
Welberry Smith MP and Baker RJ The author's reply. 2014 Transplantation pmid:24978039
Singla AK et al. Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. 2014 Transplantation pmid:24949498
Urbanowicz T et al. Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. 2014 Ann. Transplant. pmid:24949728
Andrade-Sierra J et al. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab. 2014 Nefrologia pmid:24658197
Webster P et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. 2014 Lupus pmid:24928830
Wolfram D et al. Insights from computational modeling in inflammation and acute rejection in limb transplantation. 2014 PLoS ONE pmid:24926998
Zhao X et al. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation]. 2014 Zhonghua Wai Ke Za Zhi pmid:24924566
Kanyshkova T et al. Regionally specific expression of high-voltage-activated calcium channels in thalamic nuclei of epileptic and non-epileptic rats. 2014 Mol. Cell. Neurosci. pmid:24914823
Carbajo-Lozoya J et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. 2014 Virus Res. pmid:24566223
Lin T et al. A Chinese girl with novel PLCE1 mutations and proliferation of the mesangium responded to tacrolimus therapy. 2014 Nephrology (Carlton) pmid:24533735
Rotter D et al. Calcineurin and its regulator, RCAN1, confer time-of-day changes in susceptibility of the heart to ischemia/reperfusion. 2014 J. Mol. Cell. Cardiol. pmid:24838101
Ren Y et al. Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice. 2014 Int. Immunopharmacol. pmid:24836681
Li H et al. A promising approach of overcoming the intrinsic resistance of Candida krusei to fluconazole (FLC)--combining tacrolimus with FLC. 2014 FEMS Yeast Res. pmid:24830342
Wang YB et al. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization. 2014 AAPS PharmSciTech pmid:24824172
Oda K et al. In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506). 2014 Biopharm Drug Dispos pmid:24822242
Wang Z et al. Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation. 2014 Eur. J. Clin. Pharmacol. pmid:24820765
Welzl K et al. Effect of different immunosuppressive drugs on immune cells from young and old healthy persons. 2014 Gerontology pmid:24434865
Yang LM et al. Experimental research on end-to-side anastomosis of peripheral nerves and effect of FK506 on end-to-side anastomosis. 2014 Bratisl Lek Listy pmid:25573729
Colom H et al. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. 2014 Kidney Int. pmid:24402086
Castronovo G et al. The effect of nonsurgical periodontal treatment on the severity of drug-induced gingival overgrowth in transplant patients. 2014 Quintessence Int pmid:24389563
Yap DY et al. Long-term data on tacrolimus treatment in lupus nephritis. 2014 Rheumatology (Oxford) pmid:24996908
Jin L et al. Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats. 2014 PLoS ONE pmid:24959755
Shihab FS et al. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study. 2014 Clin Transplant pmid:24754603
Taube D et al. Generic tacrolimus in solid organ transplantation. 2014 Clin Transplant pmid:24750309
Gillard P et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. 2014 Transplantation pmid:24770614
Nacif LS et al. An analysis of tacrolimus-related complications in the first 30 days after liver transplantation. 2014 Clinics (Sao Paulo) pmid:25518032
Varghese J et al. Tacrolimus-related adverse effects in liver transplant recipients: its association with trough concentrations. 2014 Indian J Gastroenterol pmid:24740447
Mitsides N et al. Dapsone-induced methemoglobinemia in renal transplant recipients: more prevalent than previously thought. 2014 Transpl Infect Dis pmid:24215452
Calabrese B et al. Activity-dependent dendritic spine shrinkage and growth involve downregulation of cofilin via distinct mechanisms. 2014 PLoS ONE pmid:24740405
Kawaguch K et al. Successful treatment with allogenic hematopoietic stem cell transplantation of a severe congenital neutropenia patient harboring a novel ELANE mutation. 2014 Rinsho Ketsueki pmid:25501410
Wan XC and Dimov V Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis. 2014 Expert Opin Drug Metab Toxicol pmid:24490943
Cvetkovic TP et al. Gender differences in oxidative and nitrosative stress parameters in kidney transplant patients on tacrolimus-based immunosuppression. 2014 Int Urol Nephrol pmid:24101297
Elens L et al. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. 2014 Br J Clin Pharmacol pmid:24118098
Langers P et al. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation. 2014 Ther Drug Monit pmid:24081208
da Cunha Filho RR et al. "Angular" plasma cell cheilitis. 2014 Dermatol. Online J. pmid:24656273
Nakamura A et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. 2014 Transplant. Proc. pmid:24656020